Cheema MR, et al. - Researchers conducted the study for determining the outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (nAMD) over 10 years in a real-world clinical setting. Ninety patients out of 196 patients (197 eyes) had 10 years of follow-up data. According to this single-centre, retrospective observational consecutive case series cohort study, over a ten-year period, anti-VEGF treatment for nAMD showed 63.3% of eyes lost ≤ 15 letters. Eyes with improved baseline vision were more likely to continue receiving anti-VEGF treatment, but the injection treatment frequency decreased.